Eli Lilly has enjoyed a successful run the past several quarters as the company's blockbuster GLP-1 weight-loss drug Wegovy ...

Wegovy was first to market but has been losing ground to Eli Lilly's Zepbound in recent months, according to the latest ...

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

The World Health Organization plans to officially back the use of weight-loss drugs to treat obesity in adults for the first ...

In an internal memo, the World Health Organization signaled its support for anti-obesity drugs like Wegovy and Zepbound, ...

Shares in Eli Lilly have weakened after CVS Health, one of the largest pharmacy benefit managers (PBMs) in the US, said it ...

The WHO's conditional recommendation will be officially released in August, as part of new guidelines on treating obesity. It ...

Amazon talks up AI potential on earnings call, points to limited tariff impact. American Airlines commits to $4 billion ...

The World Health Organization is gearing up to officially endorse weight-loss drugs to tackle obesity in adults for the first ...

The World Health Organization plans to endorse weight-loss drugs for treating obesity in adults, marking a strategic change.

Eli Lilly CEO Dave Ricks took a stand against Trump's tariffs in a Q1 earnings call. The medicine company has strong operations for obesity and weight loss drugs in Ireland.

Cameco’s fuel services business saw production of 3.9 million kilograms, up from 3.7 million a year earlier, while fuel services sales volumes totalled 2.4 million kilograms, up from 1.5 million ...